Introduction {#s0001}
============

Pancreatic neuroendocrine tumors (PanNETs) arise from the endocrine cells of the pancreas. The World Health Organization (WHO) guidelines grade these tumors as well-differentiated neuroendocrine tumors, well-differentiated neuroendocrine carcinomas and poorly differentiated neuroendocrine carcinomas.[@cit0001] Compared to the more common form of pancreatic cancer, adenocarcinoma, which arises in exocrine cells, PanNETs comprise only 2% to 5% of new pancreatic neoplasms according to current diagnostic procedures.[@cit0001] However, recent epidemiological studies also support that the overall incidence of PanNETs has increased at a statistically significant rate due to improvements in radiological imaging and clinician awareness.[@cit0003] In addition, the prevalence of PanNETs observed in autopsy studies has been shown to be as high as 10%,[@cit0002] suggesting that there may be a great number of undiagnosed, nonfunctional PanNETs in the general population.

The current approach for the treatment of PanNETs is surgical resection and management of hormone hypersecretion if feasible. PanNETs tend to grow at a slower rate and with an overall better prognosis than exocrine tumors.[@cit0001] The 5-year survival of PanNETs can be as high as 55% when the tumors are detected before metastasis and are amenable to surgical resection. Once the tumor becomes metastatic, the median overall survival rate is approximately 2 years.[@cit0005] The molecular mechanisms underlying this malignancy are poorly understood, and the 5-year survival rate has not significantly improved over the past several decades. The FDA recently approved 2 targeted therapies, sunitinib malate and everolimus, both of which have only shown a modest benefit to patients with PanNETs.[@cit0006] These shortcomings highlight the need for a better understanding of the molecular pathology of this disease and the urgency of appropriate pre-clinical models to validate potential targets to this type of cancer.

A number of signaling pathways have been shown to be involved in the tumorigenesis of pancreatic neuroendocrine cells such as PI3K signaling, mTOR pathway components and cell cycle regulators. *MEN1* is one of the most commonly mutated genes in PanNETs, with an up to 36% mutation frequency in sporadic localized neuroendocrine tumors and an up to 56% in metastatic neuroendocrine tumors.[@cit0008] Recent exon sequencing identified mutations of *ATRX*/*DAXX* both of which are involved in chromatin regulation, providing additional insights into the pathogenesis of PanNETs.[@cit0008]

The *Men1* knockout (KO) mouse mimics the phenotypes observed in patients with PanNETs. Studies on the *Men1* KO mouse show that pancreatic neuroendocrine tumors progress though 4 different stages: normal, hyperplasia, atypia and adenoma.[@cit0009] In the *Men1* conditional KO mouse model, menin is lost in pancreatic islets during embryogenesis, and hyperplastic islets can be observed as early as 2 months. However, frank tumors do not develop until 8 to 10 months of age. In addition, even though hyperplasia is observed in most, if not all of the pancreatic islets, only a small percent of hyperplastic islets ultimately develop tumors. The long tumor latency and sporadic tumor formations in the *Men1* KO mouse model indicate that deletion of *Men1* is sufficient to induce hyperplasia, but that additional somatic events may be required for further tumor progression. LOH analyses also support this notion. Loss of heterozygosity (LOH) analysis on tumors from MEN-1 patients as well as sporadic tumors found that up to 68% of PanNETs exhibit losses of large parts of chromosome 11q.[@cit0010]

*Kmt2a* (*MLL*) encodes a histone H3 lysine 4 specific methyltransferase. It is ubiquitously expressed and plays important roles in many mouse tissues and at different tumor stages.[@cit0011] Rearrangements of the human *KMT2A* gene by chromosomal translocation are associated with a variety of acute myeloid and lymphoid leukemias.[@cit0014] However, the functions of *KMT2A* in solid tumors have not been well characterized. Interestingly, KMT2A is physically associated with menin in conjunction with a number of other proteins to form a COMPASS-like complex that promotes histone H3 methylation.[@cit0015] The *KMT2A* gene is located on chromosome segment 11q23 which also frequently undergoes LOH in PanNETs. Based on these observations, we hypothesized that *Kmt2a* might be involved in tumor suppression in pancreatic islet tumors. In this study, we aim to define the role of the TrxG protein Kmt2a in pancreatic islet tumorigenesis using genetically modified mouse models.

Results {#s0002}
=======

Pancreatic islet specific loss of Kmt2a leads to hyperplasia {#s0002-0001}
------------------------------------------------------------

To address whether *Kmt2a* is required for islet development and homeostasis of adult islets, we crossed the *Kmt2a*^f/f^ mouse with a *RIP-Cre* transgenic mouse to generate *Kmt2a*^f/f^;*RIP-Cre* mice. Immunohistochemical (IHC) analysis for Kmt2a was performed on 2-month old mice to assess Kmt2a protein level changes in mouse pancreatic islets. The results were consistent with *Kmt2a* RT-PCR ([Fig. 1A](#f0001){ref-type="fig"}), with Kmt2a being highly expressed ([Fig. 1B](#f0001){ref-type="fig"}). However, the Kmt2a protein signal was almost completely lost in *Kmt2a*^f/f^;*RIP-Cre* pancreatic islets upon introduction of *RIP-Cre*([Fig. 1B](#f0001){ref-type="fig"}), suggesting that RIP-Cre could efficiently delete the *Kmt2a* allele in pancreatic islets. Islet-specific *Kmt2a* knockout mice were viable and did not show a reduced lifespan compared to control mice (data not shown). The pancreata from *Kmt2a*^f/f^;*RIP-Cre* mice and control mice were collected at 2 months, 6 months, and 10 months and were examined for islet morphology by histological analysis. At the 2-month stage and 6-month stage, the morphology and size of islets from *Kmt2a*^f/f^;*RIP-Cre* mice were almost indistinguishable from those in control mice, indicating that *Kmt2a* is not required for pancreatic islet development. However, at 10-months the islets in *Kmt2a*^f/f^;*RIP-Cre* mice were significantly larger than those in control mice, suggesting that *Kmt2a* inactivation causes a hyperplastic phenotype ([Figs. 1C and 1D](#f0001){ref-type="fig"}). Further analysis of *Kmt2a*^f/f^;*RIP-Cre* mice at 12 months and 16 months confirmed the presence of hyperplasia, but no frank tumors were detected in *Kmt2a*^f/f^;*RIP-Cre* mice (data not shown). This study indicates that ablation of *Kmt2a* can cause modest hyperplasia in mouse pancreatic islets even though *Kmt2a* loss does not lead to pancreatic islet tumors on its own. Figure 1.*Kmt2a* inactivation leads to mild islet hyperplasia in mouse pancreatic islets. (A) *Kmt2a* expression was evaluated over time in mouse pancreatic islet cells by RT-PCR. *Men1* expression served as the control. (B) Detection of Kmt2a by immunohistochemistry in *RIP-Cre, Kmt2a*^f/f^;*RIP-Cre, Men1*^f/f^;*RIP-Cre* and *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* pancreatic islets in 2-month old mice. (C) Representative H&E staining of pancreata from mice with the indicated genotypes. (Scale bar: 100μm) (D) Average pancreatic islet size. Islet size was estimated by measuring the area of an islet using Image J. The 10 largest islets were measured in each mouse, and the average islet size was generated from 80 islets for each genotype.

Ablation of Kmt2a in the Men1-deficient mouse leads to reduced survival through hyperinsulinemia and hypoglycemia {#s0002-0002}
-----------------------------------------------------------------------------------------------------------------

To address whether *Kmt2a* inactivation has biological consequences in mice with a *Men1* null background, we generated *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice. Kmt2a IHC on islets from *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice showed that the Kmt2a signal is almost completely lost ([Fig. 1B](#f0001){ref-type="fig"}). Over time, the median survival time for *Men1*^f/f^;*RIP-Cre* mice (N = 25) was 313 days, while the median survival time for *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice (N = 16)was markedly shorter at 258 days, indicating that *Kmt2a* loss shortens the life span of *Men1*-deficient mice ([Fig. 2A](#f0002){ref-type="fig"}). Similarly, within the same littermates the median survival time for *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice (N = 10) was 274 d compared to 334 d for *Men1*^f/f^;*RIP-Cre* mice (N = 12) when both *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice and *Men1*^f/f^;*RIP-Cre* mice were generated from the same littermates (Fig. S1). Figure 2.Loss of *Kmt2a* shortens life span in *Men1*-deficient mice. (A) Kaplan-Meier survival curves comparing *Men1*^*f/f*^;*RIP-Cre* mice (n = 24) with *Kmt2a*^f/f^; *Men1*^*f/f*^;*RIP-Cre* mice (n = 16; P \< 0.0001). (B) Circulating insulin levels in mice with the indicated genotypes (paired sample t test: p = 0.03 at 6 months).

The plasma insulin levels were measured at 2 months, 4 months, 6 months, 8 months and 10 months to assess hypoglycemia within the cohort. In *Men1*^f/f^;*RIP-Cre* mice the plasma insulin levels began to gradually increase at ∼4 months of age and became significantly elevated by 6 months, whereas the plasma insulin levels in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice began to rise at 4 months and then quickly surpassed *Men1*^f/f^;*RIP-Cre* mouse insulin levels ([Fig. 2B](#f0002){ref-type="fig"}). These results suggest that the combined loss of kmt2a and Men1 leads to an earlier onset of tumor formation as evidenced by hyperinsulinemia.

Ablation of Kmt2a promotes tumorigenesis in Men1-deficient pancreatic islets {#s0002-0003}
----------------------------------------------------------------------------

We harvested mouse pancreata from *Men1*^f/f^;*RIP-Cre* and from *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice and conducted histological analysis to examine pancreatic islet size. We found that the islet cell morphology and islet size in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice were indistinguishable from that in *Men1*^f/f^;*RIP-Cre* mice at age of 2 months and 4 months ([Fig. 3A](#f0003){ref-type="fig"}). However, by 6 months of age, the islets in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice were larger than those in *Men1*^f/f^;*RIP-Cre* mice. When the pancreas was harvested from both strains at the 10-month stage, the islet tumor size and the islet cell morphology in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice were consistently different from that in the *Men1*^f/f^;*RIP-Cre* mice ([Fig. 3A](#f0003){ref-type="fig"}). The average islet tumor size was 2 times larger in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice than in *Men1*^f/f^;*RIP-Cre* mice ([Fig. 3B](#f0003){ref-type="fig"}). Additionally, the size of both the nucleus and cytoplasm were larger in the *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice than that in *Men1*^f/f^;*RIP-Cre* mice ([Fig. 3A](#f0003){ref-type="fig"}).We also observed that there were a greater number of tumors detected in the *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice than that in *Men1*^f/f^;*RIP-Cre* mice. When we defined abnormal islets as being larger than 0.5 mm with showing strong vascularization, we found 5 tumors in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice on average compared to only 1.3 tumors on average in *Men1*^f/f^;*RIP-Cre* mice ([Fig. 3C](#f0003){ref-type="fig"}).In general, the tumor phenotypes in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice were more advanced than the tumors in *Men1*^f/f^;*RIP-Cre* mice (Table S1). Thus, inactivation of *Kmt2a* in pancreatic islets promotes tumor progression rather than facilitating tumor initiation. We also observed that there were more blood vessels in tumors from the *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice compared to *Men1*^f/f^;*RIP-Cre* mice (Figs. S2A and S2B). Figure 3.Ablation of *Kmt2a* accelerates *Men1*-defective pancreatic islet cell tumorigenesis. (A) Representative H&E staining of pancreata from mice with the indicated genotypes. (Scale bar: 100μm) (B) Average pancreatic islet/tumor size. Islet size was estimated by measuring the islet area (tumor in *Men1*^f/f^;*RIP-Cre* mice and *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice) using Image J. The 10 largest islets were measured in each mouse and the average islet size was generated from 100 islets for each genotype. (C) Average tumor numbers in *Men1*^f/f^;*RIP-Cre* mice and *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice.

Kmt2a loss results in more cell proliferation in hyperplastic islets and tumors in *Kmt2a*^f/f^; Men1^f/f^; *RIP-Cre* mice {#s0002-0004}
--------------------------------------------------------------------------------------------------------------------------

We next utilized immunohistochemical analysis to investigate whether the larger hyperplastic islets and increased number of tumors observed in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice were a consequence of increased cell proliferation or reduced apoptosis. We found that there were elevated numbers of mitotic cells in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice compared to *Men1*^f/f^;*RIP-Cre* mice ([Figs. 4A and 4B](#f0004){ref-type="fig"}). A PanNET is considered to be a malignant tumor if there are more than 20 mitotic cells in 10 high power fields.[@cit0016] There were approximately 20 more mitotic cells in one *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* tumor than that in a comparable the *Men1*^f/f^;*RIP-Cre* tumor([Fig. 4C](#f0004){ref-type="fig"}), indicating that tumors caused by *Men1* and *Kmt2a* loss are more proliferative than those caused by loss of *Men1* alone. Figure 4.*Kmt2a* loss leads to a robust increase in mitotic cells. Mitotic cells were observed from *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* but not in *Men1*^f/f^;*RIP-Cre* islets in (A) (lower magnification, Scale bar: 100 μm) and (B) (higher magnification, Scale bar: 100μm). Arrow indicates cells undergoing mitosis.(C): Quantification of mitotic cells from hyperplastic islets/tumors harvested from mice with the indicated genotypes at an age of 10 months.

Next we performed IHC staining for the mitotic marker H3S10P^17^in islets harvested from *RIP-Cre, Men1*^f/f^;*RIP-Cre* and *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice. As expected, the *Men1*^f/f^;*RIP-Cre* islets showed more H3S10P positive cells than *RIP-Cre* control islets ([Fig. 5A](#f0005){ref-type="fig"}). However, In *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* islets, there were many more H3S10P positive cells when compared with *Men1*^f/f^;*RIP-Cre* islets, thus demonstrating increased mitosis([Fig. 5A](#f0005){ref-type="fig"}). Quantification of H3S10P positive cells showed that there were 8 times more mitotic cells in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* islets than that in *Men1*^f/f^;*RIP-Cre* islets ([Fig. 5C](#f0005){ref-type="fig"}). Additionally, H3S10P staining in 10-month islets/tumors consistently showed more H3S10P positive cells in *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* tumors compared to that in *Men1*^f/f^;*RIP-Cre* tumors (Figs. S3A and S3C). Figure 5.More cell proliferation rather than less apoptosis is observed in *Kmt2a*^*f/f*^*;Men1*^*f/f*^*;RIP-Cre* islets in 6-month old mice. (A) Histone H3 serine 10 phosphorylation was evaluated in pancreatic islet cells at the age of 6 months with the indicated genotypes by immunohistochemistry (IHC). The dark brown color indicates positivity for Anti-Histone H3(phospho S10). (B) Apoptosis was measured via TUNEL assay. The dark brown color indicates apoptosis positive cells. (C) Quantification of proliferating cells from hyperplastic islets harvested from mice with the indicated genotypes at an age of 6 months. \* \*, P \< 0.01 (D) Quantification of apoptotic cells from hyperplastic islets harvested from mice with the indicated genotypes at an age of 6 months.

TUNEL assays performed on islets/tumors from *RIP-Cre, Men1*^f/f^;*RIP-Cre* and *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mice revealed that there were similar numbers of apoptotic cells in all 3 of the tested trains ([Figs. 5B and 5D](#f0005){ref-type="fig"}). Cleaved Caspase-3 (CC3) IHC staining was also performed in these islets; similar numbers of CC3 positive cells were observed in the islets (Figs. S3B and S3D). Statistical analyses did not show a significant difference between islets. These studies indicate that the more highly mitotic tumor phenotypes observed in *Kmt2a*^f/f^;*Men1*^f/f^; *RIP-Cre* mice were more likely due to increased cell proliferation rather than decreased apoptosis.

Discussion {#s0003}
==========

Kmt2a function during islet development and islet function in the adult stage {#s0003-0001}
-----------------------------------------------------------------------------

*Kmt2a* functions are not only critical for embryonic development, but are also essential for the maintenance of homeostasis in particular lineage/tissues such as haematopoietic stem cells as well as during neurogenesis in mouse postnatal brain.[@cit0013] *Kmt2a* is also highly expressed in mouse pancreatic islets. Our study reveals that *Kmt2a* is dispensable for islet development as there is no detectable difference in islet numbers in *Kmt2a*-deficient mice compared with *RIP-Cre* control mice. However, *Kmt2a* is required for adult islet homeostasis as the loss of *Kmt2a* was found to lead to advanced hyperplasia in adult mice. Our investigation indicates that *Kmt2a* is not a neuroendocrine-specific tumor suppressor as no tumors were observed in *Kmt2a*-deficient mice. Consistent with this observation, we did not observe any survival disadvantage upon *Kmt2a* loss in islets. Possible explanations include: *Kmt2a* function might indeed be dispensable for islet cell differentiation and/or *Kmt2a* loss might be compensated by *Kmt2a* family members such as *Kmt2b, Kmt2c*, or *Kmt2d*.

Kmt2a cooperates with *MEN1* to prevent tumor formation {#s0003-0002}
-------------------------------------------------------

*Men1*-deficent islets quickly become hyperplastic at 2 to 4 months of age. However, it takes 6 to 8 months for the hyperplastic islet to develop detectable tumors. Thus, other genetic or epigenetic alterations must likely occur to facilitate tumor progression. During human MEN-1 syndrome, *MEN1* is mutated at the germline level and the second allele is frequently lost through LOH, which often involves a broad region of 11q. As *KMT2A* is located in 11q23 within 10 Mb of the *MEN1* locus, *KMT2A* is frequently lost in tumors from patients with MEN-1 syndrome. Although *Kmt2a* loss in mice by itself does not lead to tumor formation, *Kmt2a* inactivation accelerates islet tumor progression in the *Men1*-deficient mouse. This study indicates that *Men1* is a driver and initiator of islet tumors whereas *Kmt2a* loss can facilitate tumor progression. Kmt2a might be involved in islet tumorigenesis in both a menin-dependent and a menin-independent manner. As a menin-associated protein, Kmt2a might partially compensate for menin dysfunction and maintain key downstream targets. Whereas when Kmt2a is inactivated, menin might counteract the effect caused by Kmt2a loss. On the other hand, although menin is a component of the COMPASS-like complex that promotes histone H3 methylation under certain circumstance, Kmt2a might be critical for certain important genes in pancreatic islets which are independent of menin. Our preliminary ChIP-seq and RNA-Seq data (unpublished) show that the expression of several islet-specific transcription factors is positively regulated by Kmt2a enzymatic activity, but not menin activity. Further experiments should be conducted to address these remaining questions.

Advanced mouse models for molecular pathology studies and preclinical studies {#s0003-0003}
-----------------------------------------------------------------------------

Currently two targeted therapies for pancreatic neuroendocrine tumors have been approved by the FDA,[@cit0006] indicating that targeted therapies can be developed for the treatment of pancreatic neuroendocrine cancer. However, current targeted therapies only prolong progression-free survival for approximately 6 months,[@cit0006] providing only a modest benefit to patients with this type of cancer. Additionally the response rates are very low when patients with advanced PanNETs were treated with the tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus.[@cit0006] Targeted therapeutic approaches which combine the effect of both mTOR inhibition and angiogenesis inhibition have shown substantial anti-cancer activity,[@cit0018] and new potential approaches have been proposed.[@cit0002] In principle, better mouse models will help to develop improved targeted therapies. The *Kmt2a*^f/f^;*Men1*^f/f^;*RIP-Cre* mouse has more advanced tumor phenotypes than other models, so this mouse model may be more suitable as a preclinical mouse model for testing new targeted therapies for pancreatic neuroendocrine tumors. In addition, menin is physically associated with Kmt2a, which is critical in leukemia mediated by Kmt2a fusion proteins. Several inhibitors that specifically disrupted the menin-Kmt2a interaction have been developed and pharmacologic inhibition has shown a very promising response.[@cit0019] Disruption of *Kmt2a* does not lead to phenotypes in early stage of islets whereas *Men1* deletion causes a hyperplastic phenotype, suggesting that menin has Kmt2a-independent roles in the maintenance of homeostasis in mouse pancreatic islets, which is consistent with a recent study in the haematopoietic system.[@cit0022] This observation may alleviate some concern regarding the potential strong side effect on pancreatic function when applying these MI-2 and related inhibitors in patients with *Kmt2a*-associated leukemia.

Materials and methods {#s0004}
=====================

Generation of mouse strains {#s0004-0001}
---------------------------

The creation and genotyping of *RIP-Cre* mice, *Men1*^flf^;*RIP-Cre* mice has been described previously.[@cit0023] *Kmt2a*^flf^ mice were crossed with *RIP-Cre* mice[@cit0024] to obtain *Kmt2a*^f/+^;*RIP-Cre* mice. *Kmt2a*^f/+^;*RIP-Cre* mice were crossed with *Kmt2a*^f/+^mice to generate *Kmt2a*^f/f^;*RIP-Cre* mice. *Kmt2a*^f/f^ mice were crossed with *Men1*^flf^;*RIP-Cre* mice to obtain *Kmt2a*^f/+^;*Men1*^fl+^;*RIP-Cre, Kmt2a*^f/+^;*Men1*^fl+^;*RIP-Cre* were then crossed with *Kmt2a*^f/+^;*Men1*^fl+^ mice to obtain *Kmt2a*^f/f^;*Men1*^flf^;*RIP-Cre* mice. Mice were maintained on a mixed 129s6, FVB/N, and C57BL/6 background. All mice were maintained in the research animal facility of the Dana--Farber Cancer Institute and Hefei Institutes of Physical Science Laboratory Animal Center, Chinese Academy of Sciences. All procedures were performed in accordance with the National Research Council Guide for the Care and Use of laboratory Animals and were approved by the Institutional Animal Care and Use Committee of both the Dana-Farber Cancer Institute and Hefei Institutes of Physical Science, Chinese Academy of Sciences.

Isolation of mouse pancreatic islets {#s0004-0002}
------------------------------------

Pancreatic islets were isolated as previously described.[@cit0023]

Circulating insulin measurement {#s0004-0003}
-------------------------------

Blood was collected via the submandibular vein method after the mice were fasted for 16h. Plasma was prepared by spinning a tube of fresh blood containing an anticoagulant. The circulating insulin level was measured using an ultra sensitive Mouse ELISA kit (Crystal Chemical, Downers Grove, IL, USA) according to the manufacturer\'s instructions.

Histological and immunohistochemical analysis of pancreatic tissues {#s0004-0004}
-------------------------------------------------------------------

Pancreata were collected from mice at indicated time points and fixed in 4% paraformaldehyde for 2 hours followed by dehydration and paraffin embedding. Histopathological analysis was carried out on 5-micrometer sections stained with hematoxylin and eosin. Islet morphology and tumors were examined in at least 3 cut sections for each pancreas after staining with hematoxylin and eosin. Appropriate positive and negative controls were run on matched sections for all applied antibodies. Immunohistochemical staining was performed on serial sections using antibodies against *Kmt2a* (GeneTax, GTX17959, 1:400), Anti-Histone H3(Phospho S10) (Abcam, Ab14955, 1:180), and CC3 (Thermo, PA1-24473. 1:100). Sections were counterstained in Meyer\'s hematoxylin, mounted and photographed using an Olympus microscope.

RNA isolation and RT-qPCR {#s0004-0005}
-------------------------

Total RNA was extracted using the RNeasy kit (Qiagen) from 100 to 300 mouse pancreatic islets purified from 2 mice with different genotypes according to the manufacturer\'s instructions. For RT-PCR, DNase I (Qiagen)-treated RNA samples were reverse transcribed using oligo-dT and SuperScript III (Invitrogen), with first strand cDNA for PCR created using SYBR green PCR mix (Qiagen, Valencia, California, United States) in an Applied Biosystems 7300 Real Time-PCR system (Foster City, California, United States). PCR primer pairs were designed to amplify 150- to 200-bp fragments from select genomic regions. Quantification of mRNA expression in each sample was performed by normalizing values to the expression values for *Gapdh*. Primer sequences for *Kmt2a* are 5′-CATTCGGCAAATGGAGCGAG-3′(forward) and 5′-TAGAGGAGGCTGCTCAGT GT-3′ (reverse); primer sequences for *Men1* are 5′-GATGGACATCTCTGAGACCCA-3′(forward) and 5′-CCAGTCCCTCTTCAGCTTCA-3′(reverse); primer sequences for *Gapdh* are 5′-TCAATGAAGGGGTCGTTGAT-3′ (forward) and 5′-CGTCCCGTAGACAAAATGGT-3′ (reverse).
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